Allergic bronchopulmonary Aspergillosis in children

ATAY Ö., ASİLSOY S., ATAKUL G., AL S., Kangalli Boyacioglu Ö., UZUNER N., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.5, pp.2554-2563, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.3906/sag-2104-227
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.2554-2563
  • Keywords: Allergic bronchopulmonary aspergillosis, asthma, cystic fibrosis, child, CYSTIC-FIBROSIS, SEVERE ASTHMA, OMALIZUMAB, DIAGNOSIS, SENSITIZATION, FUMIGATUS
  • Dokuz Eylül University Affiliated: Yes


Background/aim: Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature. Materials and methods: Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylul University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively. Results: The mean age of patients diagnosed with ABPA was 14.33 +/- 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004-6129), and the median AF specific IgE was 10.64 (2.59-49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications. Conclusion: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.